(Q28283241)

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

10 January 2025

0 references

1 reference

B. Fisher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

J. P. Costantino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

D. L. Wickerham

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

C. K. Redmond

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

M. Kavanah

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

W. M. Cronin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

V. Vogel

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

A. Robidoux

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

N. Dimitrov

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

J. Atkins

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

M. Daly

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

S. Wieand

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

E. Tan-Chiu

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

L. Ford

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

10 January 2025

N. Wolmark

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9747868

Journal of the National Cancer Institute

10 January 2025

publication date

16 September 1998

0 references

language of work or name

English

0 references

published in

0 references

volume

90

0 references

issue

18

0 references

page(s)

1371-88

0 references

cites work

Current overview of EORTC clinical trials with tamoxifen

1

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Tamoxifen in advanced breast cancer

10 January 2025

2

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy

10 January 2025

3

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer

10 January 2025

4

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation

10 January 2025

6

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation

10 January 2025

7

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial

10 January 2025

8

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

10 January 2025

10

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party

10 January 2025

11

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy

10 January 2025

12

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

New Perspective on Cancer of the Contralateral Breast: A Marker for Assessing Tamoxifen as a Preventive Agent

10 January 2025

13

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer

10 January 2025

14

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells

10 January 2025

17

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III

10 January 2025

18

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Effect of anti-oestrogens on initiation of mammary cancer in the female rat.

10 January 2025

19

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata

10 January 2025

20

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model

10 January 2025

21

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen

10 January 2025

22

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels

10 January 2025

23

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Tamoxifen, serum lipoproteins and cardiovascular risk

10 January 2025

24

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer

10 January 2025

25

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition

10 January 2025

26

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

The pharmacology and clinical uses of tamoxifen

10 January 2025

27

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

10 January 2025

28

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Highlights of the NSABP Breast Cancer Prevention Trial

10 January 2025

29

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

10 January 2025

30

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Designs for group sequential tests

10 January 2025

32

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative

10 January 2025

33

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Applications of crude incidence curves

10 January 2025

35

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

10 January 2025

36

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Chemoprevention of cancer

10 January 2025

39

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Prospects for the Primary Prevention of Breast Cancer

10 January 2025

40

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Aspects of the rationale for the Women's Health Trial

10 January 2025

42

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Chemoprevention of breast cancer with retinoids

10 January 2025

43

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Estrogen receptor immunohistochemistry in carcinoma in situ of the breast

10 January 2025

44

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.

10 January 2025

45

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study

10 January 2025

46

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Potential value of hormone receptor assay in carcinoma in situ of breast

10 January 2025

47

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

10 January 2025

48

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Coronary heart disease mortality and adjuvant tamoxifen therapy

10 January 2025

50

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Screening for osteoporosis

10 January 2025

51

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

10 January 2025

52

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Does tamoxifen cause cancer in humans?

10 January 2025

53

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

10 January 2025

55

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes

10 January 2025

57

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

10 January 2025

58

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients

10 January 2025

59

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

10 January 2025

60

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Long-term tamoxifen citrate use and potential ocular toxicity

10 January 2025

61

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

10 January 2025

63

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation

10 January 2025

64

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371

Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial

10 January 2025

67

1 reference

https://api.crossref.org/works/10.1093/JNCI/90.18.1371